Cancer
Malignant Kidney Neoplasm
CI-CAN-00003171Explore in graph →
Top-level453 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003171Explore in graph →
Clinical trials
2,143 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (339)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT00126659 | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2018 | clinicaltrials |
| NCT01762150 |
| Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma |
| completed |
| Phase 2 |
| 26 |
| Peking University Cancer Hospital & InstituteOTHER |
| 1 |
| Nov 20, 2018 |
| clinicaltrials |
| NCT01265368 | A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)(ASET) | completed | Phase 1 / Phase 2 | 19 | Mologen AGINDUSTRY | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00378703 | Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 361 | National Cancer Institute (NCI)NIH | 2 | Nov 14, 2018 | clinicaltrials |
| NCT03226236 | Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC(RENALVax-2) | withdrawn | Phase 2 | 0 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT02560012 | Personalized Targeted Inhibitors Treatment in Renal Cell Cancer | terminated | Phase 2 | 4 | The University of Texas Health Science Center, HoustonOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01158222 | Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer | completed | Phase 2 | 37 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT01158521 | Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer | completed | Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT01727089 | Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT02919371 | Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) | unknown | Phase 1 / Phase 2 | 77 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00089102 | Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer | terminated | Phase 2 | 9 | Medical University of South CarolinaOTHER | 1 | Jul 16, 2018 | clinicaltrials |
| NCT00090870 | PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer | terminated | Phase 2 | 10 | Medical University of South CarolinaOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT01553539 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01482949 | A Rollover Protocol for Subjects Previously Treated With AGS-003 | terminated | Phase 2 | 2 | Argos TherapeuticsINDUSTRY | 1 | Jun 27, 2018 | clinicaltrials |
| NCT00085436 | DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC | completed | Phase 2 | 18 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jun 26, 2018 | clinicaltrials |
| NCT02626754 | A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population | terminated | Phase 2 | 13 | vghtpe userOTHER_GOV | 1 | Jun 26, 2018 | clinicaltrials |
| NCT03149159 | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab | withdrawn | Phase 2 | 0 | Medical University of South CarolinaOTHER | 1 | Jun 18, 2018 | clinicaltrials |
| NCT00729053 | Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma | completed | Phase 2 | 92 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 12, 2018 | clinicaltrials |
| NCT03341845 | Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC | unknown | Phase 2 | 40 | The Netherlands Cancer InstituteOTHER | 1 | May 21, 2018 | clinicaltrials |
| NCT01829841 | A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer | completed | Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 3, 2018 | clinicaltrials |
| NCT00529802 | Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer | completed | Phase 2 | 60 | University of ChicagoOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01361113 | Neoadjuvant Pazopanib in Renal Cell Carcinoma | completed | Phase 2 | 21 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT00923130 | Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer | completed | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 17, 2018 | clinicaltrials |
| NCT03456401 | Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)(TOKIO) | terminated | Phase 2 | 18 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 7, 2018 | clinicaltrials |
| NCT02962804 | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | University of Kansas Medical CenterOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT00448721 | A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer | completed | Phase 2 | 24 | AEterna ZentarisINDUSTRY | 1 | Mar 1, 2018 | clinicaltrials |
| NCT00498966 | Ph II Study of Perifosine for Patients With Carcinoma of the Kidney | completed | Phase 2 | 50 | AEterna ZentarisINDUSTRY | 1 | Feb 5, 2018 | clinicaltrials |
| NCT00782275 | Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma | completed | Phase 2 | 41 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 24, 2018 | clinicaltrials |
| NCT01108445 | Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma(ASPEN) | completed | Phase 2 | 131 | Duke UniversityOTHER | 3 | Jan 16, 2018 | clinicaltrials |
| NCT02072044 | Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy | unknown | Phase 2 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 29, 2017 | clinicaltrials |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT00726323 | A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) | completed | Phase 2 | 74 | GlaxoSmithKlineINDUSTRY | 1 | Dec 11, 2017 | clinicaltrials |
| NCT00365287 | Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer | completed | Phase 1 / Phase 2 | 148 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT00408902 | Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer | completed | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2017 | clinicaltrials |
| NCT02122003 | Second Line Sorafenib After Pazopanib in Patients With RCC(SOAP) | terminated | Phase 2 | 16 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00278395 | Vorinostat in Treating Patients With Kidney Cancer | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Nov 14, 2017 | clinicaltrials |
| NCT01492192 | RGD-PET-CT in Cancer Angiogenesis | terminated | Phase 2 | 10 | Oxford University Hospitals NHS TrustOTHER | 1 | Nov 1, 2017 | clinicaltrials |
| NCT00331409 | Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 23 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT01784978 | Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer(SUNRISES) | terminated | Phase 2 | 41 | Associació per a la Recerca Oncologica, SpainOTHER | 3 | Oct 2, 2017 | clinicaltrials |
| NCT00003520 | Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer | terminated | Phase 2 | 15 | Burzynski Research InstituteOTHER | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00923845 | Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2017 | clinicaltrials |
| NCT02089802 | Optimizing Pazopanib Exposure in RCC Patients(OPERA) | terminated | Phase 2 | 6 | Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.OTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT02429440 | Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides(UroRCC) | unknown | Phase 1 / Phase 2 | 40 | University Hospital TuebingenOTHER | 0 | Aug 17, 2017 | clinicaltrials |
| NCT00089778 | Vaccine Treatment of Kidney Cancer | terminated | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jan 3, 2019source: clinicaltrials